A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Daphne, Alabama 36526, United States
111-111-1111
Marietta, Georgia 30060, United States
Albuquerque, New Mexico 87106, United States
Roanoke, Virginia 24014, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
ABB, Buenos Aires F.D. C1199ABB, Argentina
CABA, Buenos Aires F.D. C1430EGF, Argentina
Ina-machi, Saitama 362-0806, Japan
Bunkyo-ku, Tokyo 1138603, Japan
Koto, Tokyo 135-8550, Japan
Florești, Cluj 407280, Romania
Cheongju-si, Chungcheongbuk-do [Chungbuk] 28644, South Korea
Santiago de Compostela, A Coruña [La Coruña] 15706, Spain
Central Middlesbrough, Middlesbrough TS4 3BW, United Kingdom
239-274-9930
407-353-1915
727-216-1143
770-281-5124
309-243-3000
505-570-5835
919-684-8239
701-323-5741
000-000-0000
513-751-2273
605-209-4092
615-329-7274
512-427-9400
903-579-9800
540-381-5291
206-386-2457
206-386-2457